Abraxis Melamine Detection Kit validated for use on MDS Analytical
Technologies SpectraMax(R) microplate readers with SoftMax(R) Pro
SUNNYVALE, CA and WARMINSTER, PA, Oct. 30 /CNW/ - MDS Analytical
Technologies, a leader in innovative solutions for drug discovery and
life-sciences research, today announced that the Abraxis Melamine Detection
Kit has been validated for use on MDS Analytical Technologies' SpectraMax(R)
absorbance microplate readers with SoftMax(R) Pro 5 GxP analytical software,
an industry-standard analysis software for FDA 21 CFR Part 11 compliance.
This solution from MDS Analytical Technologies offers a cost-effective,
high-throughput, quality-assurance solution to detect melamine contamination
in such food products as milk, infant formula, pet food, and confectionery.
Melamine, an organic industrial polymer, has recently been found in
various foods and, if undetected, may cause serious illness or death. This
enzyme-linked immuno-sorbent assay (ELISA) solution will enable
quality-assurance technicians in food-safety laboratories to easily detect the
presence of melamine down to 10 parts per billion (ppb).
"Recent stories of melamine-related illnesses and deaths have made
melamine contamination a serious concern," said Andy Boorn, President of MDS
Analytical Technologies. "The pre-programmed melamine protocol in SoftMax
Pro 5 GxP software, combined with our microplate readers, enables us to offer
a more-complete high-throughput solution to better address what has become an
increasingly important consumer safety issue."
This solution further enables MDS Analytical Technologies to expand its
offering in applied markets. MDS Analytical Technologies also offers a mass
spectrometry-based solution for food safety testing introduced earlier this
year through its joint venture partnership with Applied Biosystems.
"The teams at both companies are excited to offer a cost-effective,
highly sensitive quality-control solution for the detection of melamine," said
Fernando M. Rubio, President and Chief Executive Officer of Abraxis LLC. "Our
collaboration with MDS Analytical Technologies has provided the food industry
throughout the world with an easy and affordable method to ensure foods have
not been contaminated by melamine."
SpectraMax(R) microplate readers can be integrated with the MDS
Analytical Technologies' StakMax(R) microplate handling system. Technicians
may also configure the StakMax(R) system with MDS Analytical Technologies'
AquaMax(R) 4000 microplate washer. These combinations can be used to maximize
throughput while minimizing manual plate handling.
To download application notes on this method, please visit
www.moleculardevices.com/melamine or customers can call our Customer Service
department at +1 (408) 747-1700 to speak to a sales representative.
About SpectraMax(R) Absorbance Microplate Readers
Molecular Devices, now part of MDS Analytical Technologies, is a leading
supplier of microplate reader systems to academic, pharmaceutical, and
biotechnology research groups worldwide. The Company offers several multi-mode
detection systems for ELISAs, including SpectraMax(R) M5e and SpectraMax(R)
M2e microplate readers, and SpectraMax(R) 340 PC, VersaMax(TM), VMax(R), and
EMax(R) single-mode microplate readers. The Company's SpectraMax(R) patented
technologies, such as PathCheck(R) well-volume detection, dual-monochromators,
and SmartOptics design, enable researchers more flexibility, sensitivity, and
ease-of-use for the broadest range of assays. The PathCheck(R) sensor is the
only patented technology available that measures the depth (optical
pathlength) of a sample in a microplate. When combined with SoftMax(R) Pro
software, it automatically normalizes the well absorbance to a cuvette
equivalent path-length of one centimeter. The patented dual-monochromator
design uses two scanning monochromators to determine optimal excitation and
emission settings, eliminating the need for expensive filters. Find out more
About SoftMax(R) Pro 5 GxP Analytical Software
SoftMax(R) Pro 5 GxP analytical software, which is FDA 21 CFR Part
11-compliant, raises the bar for microplate data acquisition and analysis.
This software solution, which runs on all microplate readers offered by MDS
Analytical Technologies, offers significant enhancements over previous
releases, including five parameter (5PL) logistic curve fitting; parallel line
analysis (PLA) with observation weighting; more than 120 ready-to-run assay
protocols for instant results generation; native support for Mac OS X; XML
export and multiple-destination AutoSave with new options; enhanced Windows
Interprocess Messaging for better robotics/LIMS/SDMS integration; more
detailed printed headers and footers; and full backwards-compatibility. Find
out more at http://www.moleculardevices.com/pages/software/softmax.html.
About Abraxis LLC
Abraxis LLC is a biotechnology company dedicated to the discovery,
development and delivery of core technologies that offer customers more
effective, real time testing solutions for a safer environment and food
supply. The company's portfolio includes diagnostic tests for endocrine
disrupting chemicals, antibiotics, pesticides, industrial chemicals, toxic
organics, surfactants, marine biotoxins, cyanotoxins, mycotoxins, and
veterinary residues. For more information about the company and its products,
please visit www.abraxiskits.com.
About MDS Analytical Technologies
MDS Analytical Technologies, a business unit of MDS Inc., is focused on
the research, design, manufacture and marketing of state-of-the-art tools for
mass-spectrometry, drug discovery and bioresearch. MDS Analytical
Technologies' products are designed to help accelerate the complex process of
discovering and developing new drug compounds, and are sold to research
scientists around the world. The mass-spectrometer product lines are also sold
globally through joint ventures with two of the world's leading analytical
instrumentation and life sciences companies, Applied Biosystems, Inc. and
PerkinElmer, Inc. Find out more at www.moleculardevices.com or
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has
more than 5,500 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information:
For further information: Media: Cheri Salazar, MDS Analytical
Technologies, (408) 548-6316, email@example.com; Investors: Kim Lee,
MDS Inc., (416) 213-4721, firstname.lastname@example.org